Market Research Logo

TG Therapeutics Inc (TGTX) - Financial and Strategic SWOT Analysis Review

TG Therapeutics Inc (TGTX) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and autoimmune diseases. The company develops two therapies, namely, TG-1101 (ublituximab) and TGR-1202 for the treatment of hematological malignancies. TG-1101 glycoengineered monoclonal antibody that targets a unique epitope on the B-lymphocyte CD20 antigen and TG-1202 is an orally available PI3K delta inhibitor. Its other product candidates include inhibitors of IRAK4 and anti-PD-L1 and anti-GITR antibodies. The company also offers products and technologies for in-licensing, partnership, acquisition and/or investment. TG Therapeutics is headquartered in New York City, New York, the US.

TG Therapeutics Inc Key Recent Developments

Jun 04,2018: TG Therapeutics Names Adam Waldman As Chief Commercial Officer
May 08,2018: TG Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results
Nov 08,2017: TG Therapeutics Provides Business Update and Reports Third Quarter 2017 Financial Results
Aug 09,2017: TG Therapeutics Provides Business Update and Reports Second Quarter 2017 Financial Results
May 05,2017: TG Therapeutics Provides Business Update and Reports First Quarter 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
TG Therapeutics Inc - Key Facts
TG Therapeutics Inc - Key Employees
TG Therapeutics Inc - Key Employee Biographies
TG Therapeutics Inc - Major Products and Services
TG Therapeutics Inc - History
TG Therapeutics Inc - Company Statement
TG Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
TG Therapeutics Inc - Business Description
TG Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
TG Therapeutics Inc - Strengths
TG Therapeutics Inc - Weaknesses
TG Therapeutics Inc - Opportunities
TG Therapeutics Inc - Threats
TG Therapeutics Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
TG Therapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 08, 2018: TG Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results
Nov 08, 2017: TG Therapeutics Provides Business Update and Reports Third Quarter 2017 Financial Results
Aug 09, 2017: TG Therapeutics Provides Business Update and Reports Second Quarter 2017 Financial Results
May 05, 2017: TG Therapeutics Provides Business Update and Reports First Quarter 2017 Financial Results
Mar 10, 2017: TG Therapeutics Announces Fourth Quarter and Year-End 2016 Financial Results and Business Update
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
TG Therapeutics Inc, Key Facts
TG Therapeutics Inc, Key Employees
TG Therapeutics Inc, Key Employee Biographies
TG Therapeutics Inc, Major Products and Services
TG Therapeutics Inc, History
TG Therapeutics Inc, Subsidiaries
TG Therapeutics Inc, Key Competitors
TG Therapeutics Inc, Ratios based on current share price
TG Therapeutics Inc, Annual Ratios
TG Therapeutics Inc, Annual Ratios (Cont...1)
TG Therapeutics Inc, Interim Ratios
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
TG Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
TG Therapeutics Inc, Performance Chart (2013 - 2017)
TG Therapeutics Inc, Ratio Charts
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
TG Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report